<DOC>
	<DOC>NCT00509457</DOC>
	<brief_summary>To examine the safety and efficacy of telomerase peptide vaccination ( stimulation of the immune system) in patients with NSCLC after having been treated with conventional therapy with radiotherapy and docetaxel as a radiosensitizer.</brief_summary>
	<brief_title>GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description>Survival in patients with locally advanced, inoperable NSCLC may be improved if local control can be achieved with concurrent chemo radiotherapy .After completed standard chemo-and radiation therapy; the safety and efficacy of vaccination therapy will be measured as time to progression after treatment with GV1001. Analysis of changes in T-cell subpopulations and cytokines in peripheral blood will be performed.</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Patients with inoperable NSCLC, disease stage IIIA and stage IIIB, who has received concurrent chemoradiotherapy( typically docetaxel 20 mg/m2 and 3D radiotherapy, 2Gy x 30 within the last 4 weeks. No sign of brain metastasis( excluded by MRI of the brain) Male or female above the age of 18 years. Normal lab. values</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>NSCLC, vaccination</keyword>
	<keyword>Inoperable NSCLC stage IIIA/B in good performance status</keyword>
</DOC>